Compare ARDX & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | CMP |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2014 | 2003 |
| Metric | ARDX | CMP |
|---|---|---|
| Price | $5.09 | $29.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $15.14 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 3.4M | 326.3K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.73 |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $37.75 | N/A |
| Revenue Next Year | $34.24 | $1.29 |
| P/E Ratio | ★ N/A | $40.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $16.40 |
| 52 Week High | $8.40 | $34.50 |
| Indicator | ARDX | CMP |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 49.22 |
| Support Level | $4.95 | $28.05 |
| Resistance Level | $5.34 | $30.54 |
| Average True Range (ATR) | 0.17 | 0.97 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 21.12 | 50.54 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.